^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    gemcitabine

    i
    Other names: dFdC, LY 188011, LY188011, LY-188011
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    1d
    TransStar101: A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=150, Active, not recruiting, Suzhou Transcenta Therapeutics Co., Ltd. | Trial completion date: Sep 2025 --> Nov 2026 | Trial primary completion date: May 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • osemitamab (TST001)
    1d
    Gemcitabine-cisplatin chemotherapy plus anti-PD-L1 therapy reinvigorates antitumor immune response by reprogramming the intrahepatic cholangiocarcinoma microenvironment. (PubMed, Front Immunol)
    Our scRNA-seq analyses revealed significant alterations in the tumor microenvironment following GCP therapy: tumor-infiltrating macrophages underwent a distinct antitumor phenotypic shift, transitioning from M2 toward M1 polarization; concurrently, CD8+ T cells exhibited enhanced costimulatory signaling characterized by CD81 upregulation and malignant cells demonstrated diminished immune escape characteristics alongside heightened activity in immune response-related pathways. Our preliminary findings reveal a generally reactivated antitumor immune response in ICC following GCP therapy, which could partly illuminate the enigmatic black box of intra-tumoral cellular states associated with treatment response.
    Journal
    |
    CD8 (cluster of differentiation 8) • SPP1 (Secreted Phosphoprotein 1) • CCL18 (C-C Motif Chemokine Ligand 18) • CD81 (CD81 Molecule)
    |
    cisplatin • gemcitabine
    1d
    Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities (clinicaltrials.gov)
    P1, N=9, Terminated, Wake Forest University Health Sciences | N=27 --> 9 | Recruiting --> Terminated; Terminated due to low accruals
    Enrollment change • Trial termination
    |
    gemcitabine • docetaxel
    2d
    Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P3, N=228, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    carboplatin • gemcitabine
    2d
    A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=252, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • gemcitabine • albumin-bound paclitaxel
    3d
    A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, GlaxoSmithKline
    New P3 trial • Platinum resistant
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • mocertatug rezetecan (GSK5733584)
    3d
    Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer (clinicaltrials.gov)
    P2, N=23, Completed, Emory University | Active, not recruiting --> Completed
    Trial completion
    |
    gemcitabine • albumin-bound paclitaxel • Xermelo (telotristat etiprate)
    3d
    CUL2 confers ferroptosis resistance in pancreatic cancer by disrupting KEAP1-mediated NRF2 degradation. (PubMed, Cancer Cell Int)
    Our findings reveal a novel mechanism whereby CUL2 promotes PC progression and ferroptosis resistance through regulation of the KEAP1-NRF2 axis. CUL2 overexpression enhances cellular antioxidant capacity and maintains mitochondrial integrity, thereby conferring broad resistance to ferroptosis-inducing conditions. This study suggests that targeting the CUL2-NRF2 axis to enhance ferroptosis sensitivity might represent a promising therapeutic strategy for PC treatment.
    Journal
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • CUL2 (Cullin 2)
    |
    gemcitabine • MG132
    3d
    A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    gemcitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • BMS‐986504
    3d
    A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer (clinicaltrials.gov)
    P2, N=57, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Dec 2024 --> May 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • Koselugo (selumetinib)
    3d
    High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=29, Not yet recruiting, Emory University | Trial completion date: Feb 2027 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • gemcitabine • albumin-bound paclitaxel
    3d
    Dual pH-Responsive Calcium Phosphate Nanoparticles Conjugated with Folate by CuAAC Click Chemistry for Targeted Gemcitabine Delivery to Cancer Cells. (PubMed, ACS Appl Bio Mater)
    GEM-loaded CaP NPs showed high cytotoxicity in FRα-overexpressing cancer cell lines (MCF-7, MDA-MB-231, HeLa), while FA conjugation significantly reduced toxicity in hMSCs without compromising anticancer activity. These findings demonstrate the potential of FA-conjugated and GEM-loaded CaP NPs as a nanoplatform for targeted cancer therapy with reduced toxicity in healthy cells.
    Journal
    |
    FOLR1 ( Folate receptor alpha )
    |
    gemcitabine